This paper considers the following questions:
- How much do specialty drugs add to prescription drug costs for commercial plan payors, including insurers and employers?
- How will individuals' out-of-pocket costs vary with benefit design?
- How can payors (insurers and employers) reduce prescription drug costs without using specialty tiers?
This study is intended to convey information about the relationship between benefit designs, costs to payors, and member's out-of-pocket costs for specialty drugs.